2ny6 › Citations

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD
Nature 445 732-7 (2007)
Related entries: 2nxy, 2nxz, 2ny0, 2ny1, 2ny2, 2ny3, 2ny4, 2ny5, 2ny7

Cited: 573 times
EuropePMC logo PMID: 17301785

Abstract

The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency virus type 1 (HIV-1) envelope (Env), including substantial rearrangement of the gp120 glycoprotein upon binding the CD4 receptor, allow it to evade antibody-mediated neutralization. Despite this complexity, the HIV-1 Env must retain conserved determinants that mediate CD4 binding. To evaluate how these determinants might provide opportunities for antibody recognition, we created variants of gp120 stabilized in the CD4-bound state, assessed binding of CD4 and of receptor-binding-site antibodies, and determined the structure at 2.3 A resolution of the broadly neutralizing antibody b12 in complex with gp120. b12 binds to a conformationally invariant surface that overlaps a distinct subset of the CD4-binding site. This surface is involved in the metastable attachment of CD4, before the gp120 rearrangement required for stable engagement. A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1.

Reviews - 2ny6 mentioned but not cited (1)

  1. Tools to therapeutically harness the human antibody response. Wilson PC, Andrews SF. Nat Rev Immunol 12 709-719 (2012)


Reviews citing this publication (113)

  1. HIV-1 antiretroviral drug therapy. Arts EJ, Hazuda DJ. Cold Spring Harb Perspect Med 2 a007161 (2012)
  2. HIV-1 neutralizing antibodies: understanding nature's pathways. Mascola JR, Haynes BF. Immunol Rev 254 225-244 (2013)
  3. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Kwong PD, Mascola JR. Immunity 37 412-425 (2012)
  4. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Burton DR, Hangartner L. Annu Rev Immunol 34 635-659 (2016)
  5. Antibodies in HIV-1 vaccine development and therapy. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Science 341 1199-1204 (2013)
  6. The role of antibodies in HIV vaccines. Mascola JR, Montefiori DC. Annu Rev Immunol 28 413-444 (2010)
  7. A Blueprint for HIV Vaccine Discovery. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. Cell Host Microbe 12 396-407 (2012)
  8. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. Checkley MA, Luttge BG, Freed EO. J Mol Biol 410 582-608 (2011)
  9. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Kwong PD, Mascola JR, Nabel GJ. Nat Rev Immunol 13 693-701 (2013)
  10. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. Nat Rev Microbiol 6 143-155 (2008)
  11. Challenges in the development of an HIV-1 vaccine. Barouch DH. Nature 455 613-619 (2008)
  12. Resveratrol: its biologic targets and functional activity. Pervaiz S, Holme AL. Antioxid Redox Signal 11 2851-2897 (2009)
  13. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Montero M, van Houten NE, Wang X, Scott JK. Microbiol Mol Biol Rev 72 54-84, table of contents (2008)
  14. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Nature 446 1038-1045 (2007)
  15. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Walker LM, Burton DR. Curr Opin Immunol 22 358-366 (2010)
  16. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Zolla-Pazner S, Cardozo T. Nat Rev Immunol 10 527-535 (2010)
  17. HIV-1 and influenza antibodies: seeing antigens in new ways. Kwong PD, Wilson IA. Nat Immunol 10 573-578 (2009)
  18. Bridging the knowledge gaps in vaccine design. Rappuoli R. Nat Biotechnol 25 1361-1366 (2007)
  19. The Antibody Response against HIV-1. Overbaugh J, Morris L. Cold Spring Harb Perspect Med 2 a007039 (2012)
  20. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Murin CD, Wilson IA, Ward AB. Nat Microbiol 4 734-747 (2019)
  21. Structure-based antigen design: a strategy for next generation vaccines. Dormitzer PR, Ulmer JB, Rappuoli R. Trends Biotechnol 26 659-667 (2008)
  22. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Kwong PD, Mascola JR, Nabel GJ. Cold Spring Harb Perspect Med 1 a007278 (2011)
  23. Glycopeptide analysis by mass spectrometry. Dalpathado DS, Desaire H. Analyst 133 731-738 (2008)
  24. HIV broadly neutralizing antibody targets. Wibmer CK, Moore PL, Morris L. Curr Opin HIV AIDS 10 135-143 (2015)
  25. Vaccinology in the genome era. Rinaudo CD, Telford JL, Rappuoli R, Seib KL. J Clin Invest 119 2515-2525 (2009)
  26. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. van Gils MJ, Sanders RW. Virology 435 46-56 (2013)
  27. Challenges for structure-based HIV vaccine design. Schief WR, Ban YE, Stamatatos L. Curr Opin HIV AIDS 4 431-440 (2009)
  28. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Julien JP, Lee PS, Wilson IA. Immunol Rev 250 180-198 (2012)
  29. Cell entry of enveloped viruses. Plemper RK. Curr Opin Virol 1 92-100 (2011)
  30. Insights into the trimeric HIV-1 envelope glycoprotein structure. Ward AB, Wilson IA. Trends Biochem Sci 40 101-107 (2015)
  31. Nanobodies®: new ammunition to battle viruses. Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X. Antiviral Res 92 389-407 (2011)
  32. Toward an antibody-based HIV-1 vaccine. Hoxie JA. Annu Rev Med 61 135-152 (2010)
  33. HIV-1 vaccine development after STEP. Barouch DH, Korber B. Annu Rev Med 61 153-167 (2010)
  34. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G. Curr HIV Res 11 378-387 (2013)
  35. Survey of the year 2007 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 21 355-400 (2008)
  36. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. Seib KL, Dougan G, Rappuoli R. PLoS Genet 5 e1000612 (2009)
  37. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Forsell MN, Schief WR, Wyatt RT. Curr Opin HIV AIDS 4 380-387 (2009)
  38. Advances in structure-based vaccine design. Kulp DW, Schief WR. Curr Opin Virol 3 322-331 (2013)
  39. Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. Yu L, Guan Y. Front Immunol 5 250 (2014)
  40. Innate immune sensing of HIV-1 by dendritic cells. Luban J. Cell Host Microbe 12 408-418 (2012)
  41. HIV-1 envelope glycoprotein structure. Merk A, Subramaniam S. Curr Opin Struct Biol 23 268-276 (2013)
  42. Specificity of the autologous neutralizing antibody response. Moore PL, Gray ES, Morris L. Curr Opin HIV AIDS 4 358-363 (2009)
  43. Advances in antiviral vaccine development. Graham BS. Immunol Rev 255 230-242 (2013)
  44. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Cagigi A, Nilsson A, De Milito A, Chiodi F. Vaccine 26 3016-3025 (2008)
  45. HIV envelope: challenges and opportunities for development of entry inhibitors. Caffrey M. Trends Microbiol 19 191-197 (2011)
  46. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Pancera M, Changela A, Kwong PD. Curr Opin HIV AIDS 12 229-240 (2017)
  47. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Koff WC. Vaccine 30 4310-4315 (2012)
  48. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Willey S, Aasa-Chapman MM. Trends Microbiol 16 596-604 (2008)
  49. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Korber B, Gnanakaran S. Curr Opin HIV AIDS 4 408-417 (2009)
  50. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS. Expert Opin Biol Ther 9 355-368 (2009)
  51. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. Phogat S, Wyatt RT, Karlsson Hedestam GB. J Intern Med 262 26-43 (2007)
  52. The design and evaluation of HIV-1 vaccines. Saunders KO, Rudicell RS, Nabel GJ. AIDS 26 1293-1302 (2012)
  53. Computational tools for epitope vaccine design and evaluation. He L, Zhu J. Curr Opin Virol 11 103-112 (2015)
  54. Prospects for an HIV vaccine: leading B cells down the right path. Moir S, Malaspina A, Fauci AS. Nat Struct Mol Biol 18 1317-1321 (2011)
  55. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Brady JM, Baltimore D, Balazs AB. Immunol Rev 275 324-333 (2017)
  56. HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Li G, De Clercq E. Microbiol Mol Biol Rev 80 679-731 (2016)
  57. The changing face of HIV vaccine research. Kwong PD, Mascola JR, Nabel GJ. J Int AIDS Soc 15 17407 (2012)
  58. Structure-based vaccine design in HIV: blind men and the elephant? Pejchal R, Wilson IA. Curr Pharm Des 16 3744-3753 (2010)
  59. C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. Steckbeck JD, Kuhlmann AS, Montelaro RC. J Gen Virol 94 1-19 (2013)
  60. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Van Regenmortel MH. Arch Virol 157 1-20 (2012)
  61. Antibodies against viruses: passive and active immunization. Law M, Hangartner L. Curr Opin Immunol 20 486-492 (2008)
  62. Limitations to the structure-based design of HIV-1 vaccine immunogens. Van Regenmortel MH. J Mol Recognit 24 741-753 (2011)
  63. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD. Curr Opin HIV AIDS 8 382-392 (2013)
  64. Scientific and policy challenges to development of an AIDS vaccine. Berkley SF, Koff WC. Lancet 370 94-101 (2007)
  65. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. AIDS Patient Care STDS 30 291-306 (2016)
  66. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. Benjelloun F, Lawrence P, Verrier B, Genin C, Paul S. J Virol 86 13152-13163 (2012)
  67. Immunogen design for HIV-1 and influenza. Rathore U, Kesavardhana S, Mallajosyula VV, Varadarajan R. Biochim Biophys Acta 1844 1891-1906 (2014)
  68. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Hearty S, Conroy PJ, Ayyar BV, Byrne B, O'Kennedy R. Expert Rev Vaccines 9 645-664 (2010)
  69. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Wu X, Kong XP. Curr Opin Immunol 42 56-64 (2016)
  70. HIV sexual transmission and microbicides. Ariën KK, Jespers V, Vanham G. Rev Med Virol 21 110-133 (2011)
  71. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Acharya P, Lusvarghi S, Bewley CA, Kwong PD. Expert Opin Ther Targets 19 765-783 (2015)
  72. Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. Nikolic DS, Piguet V. J Invest Dermatol 130 352-361 (2010)
  73. Current progress in the development of a prophylactic vaccine for HIV-1. Gamble LJ, Matthews QL. Drug Des Devel Ther 5 9-26 (2010)
  74. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. Pu J, Wang Q, Xu W, Lu L, Jiang S. Viruses 11 E705 (2019)
  75. Neutralizing antibodies and control of HIV: moves and countermoves. Hessell AJ, Haigwood NL. Curr HIV/AIDS Rep 9 64-72 (2012)
  76. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS. Adv Pharmacol 55 33-97 (2007)
  77. Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Chen W, Ying T, Dimitrov DS. Expert Opin Biol Ther 13 657-671 (2013)
  78. Evolution of B cell analysis and Env trimer redesign. Karlsson Hedestam GB, Guenaga J, Corcoran M, Wyatt RT. Immunol Rev 275 183-202 (2017)
  79. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA. J Pept Sci 19 127-140 (2013)
  80. Engineering broadly neutralizing antibodies for HIV prevention and therapy. Hua CK, Ackerman ME. Adv Drug Deliv Rev 103 157-173 (2016)
  81. Peptide inhibition of HIV-1: current status and future potential. Kaushik-Basu N, Basu A, Harris D. BioDrugs 22 161-175 (2008)
  82. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Ringel O, Vieillard V, Debré P, Eichler J, Büning H, Dietrich U. Viruses 10 E197 (2018)
  83. Vaccines based on structure-based design provide protection against infectious diseases. Thomas S, Luxon BA. Expert Rev Vaccines 12 1301-1311 (2013)
  84. Broadly Neutralizing Antibodies against HIV: Back to Blood. Dashti A, DeVico AL, Lewis GK, Sajadi MM. Trends Mol Med 25 228-240 (2019)
  85. Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Wang Q, Zhang L. Front Med 14 30-42 (2020)
  86. 25 years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines. Scherer E, Douek D, McMichael A. Clin Exp Immunol 154 6-14 (2008)
  87. Accessing the human repertoire for broadly neutralizing HIV antibodies. Hammond PW. MAbs 2 157-164 (2010)
  88. Back to the future: covalent epitope-based HIV vaccine development. Paul S, Planque S, Nishiyama Y, Escobar M, Hanson C. Expert Rev Vaccines 9 1027-1043 (2010)
  89. Mucosal vaccines against respiratory syncytial virus. Yang K, Varga SM. Curr Opin Virol 6 78-84 (2014)
  90. Neutralizing Antibodies Targeting HIV-1 gp41. Caillat C, Guilligay D, Sulbaran G, Weissenhorn W. Viruses 12 E1210 (2020)
  91. Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. Bellows ML, Floudas CA. Curr Drug Targets 11 264-278 (2010)
  92. Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. Jaworski JP, Vendrell A, Chiavenna SM. Front Immunol 7 661 (2016)
  93. Passive immunization against HIV/AIDS by antibody gene transfer. Yang L, Wang P. Viruses 6 428-447 (2014)
  94. Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction. Fumakia M, Yang S, Gu J, Ho EA. Rev Med Virol 26 4-20 (2016)
  95. Synthetic antibody mimics for the inhibition of protein-ligand interactions. Haußner C, Lach J, Eichler J. Curr Opin Chem Biol 40 72-77 (2017)
  96. Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies. Flemming J, Wiesen L, Herschhorn A. AIDS Res Hum Retroviruses 34 794-803 (2018)
  97. Inhibition of HIV-1 entry: multiple keys to close the door. Hertje M, Zhou M, Dietrich U. ChemMedChem 5 1825-1835 (2010)
  98. Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. Dustin LB, Charles ED. Antivir Ther 17 1449-1452 (2012)
  99. Profiling the IgOme: meeting the challenge. Weiss-Ottolenghi Y, Gershoni JM. FEBS Lett 588 318-325 (2014)
  100. Plant made anti-HIV microbicides--a field of opportunity. Lotter-Stark HC, Rybicki EP, Chikwamba RK. Biotechnol Adv 30 1614-1626 (2012)
  101. Universal vaccines: shifting to one for many or shooting too high too soon! Hamad M. APMIS 119 565-573 (2011)
  102. A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target. Parker Miller E, Finkelstein MT, Erdman MC, Seth PC, Fera D. Viruses 13 1774 (2021)
  103. AIDS: is there an answer to the global pandemic? The immune system in HIV infection and control. Maplanka C. Viral Immunol 20 331-342 (2007)
  104. Structures of viral membrane proteins by high-resolution cryoEM. Zhou ZH. Curr Opin Virol 5 111-119 (2014)
  105. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines. Hassapis KA, Stylianou DC, Kostrikis LG. Viruses 6 5047-5076 (2014)
  106. Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy. Tung Yep A, Takeuchi Y, Engelhardt OG, Hufton SE. Biomolecules 11 407 (2021)
  107. Potential utility of GB virus type C as a preventive vaccine for HIV-1. Bagasra O, Bagasra AU, Sheraz M, Pace DG. Expert Rev Vaccines 11 335-347 (2012)
  108. Antibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality. Belogurov A, Smirnov I, Ponomarenko N, Gabibov A. FEBS Lett 586 2966-2973 (2012)
  109. Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments. Shivatare SS, Shivatare VS, Wong CH. Chem Rev 122 15603-15671 (2022)
  110. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. Uversky VN. Arch Virol 166 1283-1296 (2021)
  111. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. Timofeeva A, Sedykh S, Nevinsky G. Vaccines (Basel) 10 384 (2022)
  112. Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines. Albert J, Chiodi F, Fenyö EM. J Intern Med 262 2-4 (2007)
  113. [Structural mechanism of immune evasion of HIV-1 gp120 by genomic, computational, and experimental science]. Yokoyama M. Uirusu 61 49-57 (2011)

Articles citing this publication (459)

  1. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. Science 329 856-861 (2010)
  2. Antibody recognition of a highly conserved influenza virus epitope. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Science 324 246-251 (2009)
  3. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. Science 329 811-817 (2010)
  4. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. Nature 458 636-640 (2009)
  5. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. Science 333 1593-1602 (2011)
  6. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. Nature 480 336-343 (2011)
  7. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. Science 342 1477-1483 (2013)
  8. Molecular architecture of native HIV-1 gp120 trimers. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Nature 455 109-113 (2008)
  9. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. Science 334 1097-1103 (2011)
  10. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. Science 342 592-598 (2013)
  11. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Nature 514 455-461 (2014)
  12. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. Nat Med 15 951-954 (2009)
  13. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC. J Virol 83 7337-7348 (2009)
  14. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS. Nat Immunol 9 301-309 (2008)
  15. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR. Nat Med 13 1032-1034 (2007)
  16. Hepatitis C virus E2 envelope glycoprotein core structure. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M. Science 342 1090-1094 (2013)
  17. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. Nat Struct Mol Biol 20 796-803 (2013)
  18. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-Pazner S, Baxa U, Schön A, Freire E, Shapiro L, Lee KK, Arthos J, Munro JB, Blanchard SC, Mothes W, Binley JM, McDermott AB, Mascola JR, Kwong PD. Nat Struct Mol Biol 22 522-531 (2015)
  19. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD. Proc Natl Acad Sci U S A 107 1166-1171 (2010)
  20. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. Science 326 1123-1127 (2009)
  21. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS, NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD. Cell 161 1280-1292 (2015)
  22. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. J Virol 88 2489-2507 (2014)
  23. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Grant OC, Montgomery D, Ito K, Woods RJ. Sci Rep 10 14991 (2020)
  24. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. Proc Natl Acad Sci U S A 105 3739-3744 (2008)
  25. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR. J Virol 85 8954-8967 (2011)
  26. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC. PLoS One 8 e75665 (2013)
  27. Super-resolution biomolecular crystallography with low-resolution data. Schröder GF, Levitt M, Brunger AT. Nature 464 1218-1222 (2010)
  28. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. Proc Natl Acad Sci U S A 109 5663-5668 (2012)
  29. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD. J Virol 84 8098-8110 (2010)
  30. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JL, Subramaniam S. PLoS Pathog 8 e1002797 (2012)
  31. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, Sheng Z, Zhang B, O'Dell S, McKee K, Georgiev IS, Chuang GY, Longo NS, Lynch RM, Saunders KO, Soto C, Srivatsan S, Yang Y, Bailer RT, Louder MK, NISC Comparative Sequencing Program, Mullikin JC, Connors M, Kwong PD, Mascola JR, Shapiro L. Cell 161 470-485 (2015)
  32. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD, Sodroski J. Mol Cell 37 656-667 (2010)
  33. Few and far between: how HIV may be evading antibody avidity. Klein JS, Bjorkman PJ. PLoS Pathog 6 e1000908 (2010)
  34. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O'Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD. Science 340 751-756 (2013)
  35. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. Proc Natl Acad Sci U S A 107 11483-11488 (2010)
  36. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. PLoS Pathog 5 e1000594 (2009)
  37. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Azoitei ML, Correia BE, Ban YE, Carrico C, Kalyuzhniy O, Chen L, Schroeter A, Huang PS, McLellan JS, Kwong PD, Baker D, Strong RK, Schief WR. Science 334 373-376 (2011)
  38. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L. J Virol 83 8925-8937 (2009)
  39. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, Kraft Z, Carrico C, Boni E, Sather DN, Zenobia C, Burke KY, Bradley-Hewitt T, Bruhn-Johannsen JF, Kalyuzhniy O, Baker D, Strong RK, Stamatatos L, Schief WR. Structure 18 1116-1126 (2010)
  40. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM. Proc Natl Acad Sci U S A 113 E3413-22 (2016)
  41. Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Ozorowski G, Pallesen J, de Val N, Lyumkis D, Cottrell CA, Torres JL, Copps J, Stanfield RL, Cupo A, Pugach P, Moore JP, Wilson IA, Ward AB. Nature 547 360-363 (2017)
  42. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL. PLoS Pathog 9 e1003738 (2013)
  43. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. PLoS Pathog 6 e1001249 (2010)
  44. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L. PLoS Pathog 9 e1003106 (2013)
  45. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Bartesaghi A, Merk A, Borgnia MJ, Milne JL, Subramaniam S. Nat Struct Mol Biol 20 1352-1357 (2013)
  46. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S. Proc Natl Acad Sci U S A 108 11440-11445 (2011)
  47. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, Liao HX, Kelsoe G, Haynes BF. Proc Natl Acad Sci U S A 107 181-186 (2010)
  48. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L, CAPRISA 002 Study, CAPRISA 002 Study. J Virol 85 3128-3141 (2011)
  49. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, McGee-Estrada K, Mefford M, Gabuzda D, Smith AB, Sodroski J. PLoS Pathog 5 e1000360 (2009)
  50. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, Williamson C, Morris L, CAPRISA 002 Study Team, CAPRISA 002 Study Team. J Virol 82 1860-1869 (2008)
  51. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, Yang X, Sodroski J. Nat Struct Mol Biol 19 893-899 (2012)
  52. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Gorman J, Soto C, Yang MM, Davenport TM, Guttman M, Bailer RT, Chambers M, Chuang GY, DeKosky BJ, Doria-Rose NA, Druz A, Ernandes MJ, Georgiev IS, Jarosinski MC, Joyce MG, Lemmin TM, Leung S, Louder MK, McDaniel JR, Narpala S, Pancera M, Stuckey J, Wu X, Yang Y, Zhang B, Zhou T, NISC Comparative Sequencing Program, Mullikin JC, Baxa U, Georgiou G, McDermott AB, Bonsignori M, Haynes BF, Moore PL, Morris L, Lee KK, Shapiro L, Mascola JR, Kwong PD. Nat Struct Mol Biol 23 81-90 (2016)
  53. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, Druz A, Geng H, McKee K, Kwon YD, O'Dell S, Sastry M, Schmidt SD, Xu K, Chen L, Chen RE, Louder MK, Pancera M, Wanninger TG, Zhang B, Zheng A, Farney SK, Foulds KE, Georgiev IS, Joyce MG, Lemmin T, Narpala S, Rawi R, Soto C, Todd JP, Shen CH, Tsybovsky Y, Yang Y, Zhao P, Haynes BF, Stamatatos L, Tiemeyer M, Wells L, Scorpio DG, Shapiro L, McDermott AB, Mascola JR, Kwong PD. Cell Rep 19 719-732 (2017)
  54. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. PLoS Pathog 12 e1005520 (2016)
  55. The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, McNally JP, Ogundare O, Pascuccio M, Patel N, Wei D, Fauci AS, Arthos J. PLoS Pathog 7 e1001301 (2011)
  56. Conserved structural elements in the V3 crown of HIV-1 gp120. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. Nat Struct Mol Biol 17 955-961 (2010)
  57. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, Phogat A, Chakrabarti BK, Li Y, Shaw G, Kwong PD, Nabel GJ, Mascola JR, Wyatt RT. PLoS Pathog 5 e1000445 (2009)
  58. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, Moldoveanu Z, Elliott MC, Wilson L, Brown R, Jancova D, Barnes S, Vrbkova J, Tomana M, Smith PD, Mestecky J, Renfrow MB, Novak J. J Biol Chem 285 20860-20869 (2010)
  59. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, Wu X, Mascola JR. J Virol 89 4201-4213 (2015)
  60. The development of CD4 binding site antibodies during HIV-1 infection. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, CHAVI 001 Clinical Team Members, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. J Virol 86 7588-7595 (2012)
  61. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR. J Virol 89 2659-2671 (2015)
  62. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B. PLoS Pathog 7 e1002209 (2011)
  63. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE, Wilson IA. Nat Struct Mol Biol 20 363-370 (2013)
  64. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. Science 346 1380-1383 (2014)
  65. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW. J Virol 84 5637-5655 (2010)
  66. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Guttman M, Cupo A, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK. Nat Commun 6 6144 (2015)
  67. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB, Sodroski J. PLoS Pathog 7 e1002101 (2011)
  68. Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop. Wang H, Cohen AA, Galimidi RP, Gristick HB, Jensen GJ, Bjorkman PJ. Proc Natl Acad Sci U S A 113 E7151-E7158 (2016)
  69. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. J Virol 86 4394-4403 (2012)
  70. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, Vainshtein J, Li Y, Sodroski J, Kwong PD, Mascola JR, Wyatt R. J Virol 81 5579-5593 (2007)
  71. Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. Cao L, Pauthner M, Andrabi R, Rantalainen K, Berndsen Z, Diedrich JK, Menis S, Sok D, Bastidas R, Park SR, Delahunty CM, He L, Guenaga J, Wyatt RT, Schief WR, Ward AB, Yates JR, Burton DR, Paulson JC. Nat Commun 9 3693 (2018)
  72. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, Kwong PD. J Virol 84 2955-2962 (2010)
  73. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, de Haard H, Weiss RA. J Virol 82 12069-12081 (2008)
  74. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Günthard HF, Rusert P, Trkola A. J Exp Med 208 439-454 (2011)
  75. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, Chen XS, Wang Y. Retrovirology 10 14 (2013)
  76. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Günthard HF, Trkola A. J Exp Med 208 1419-1433 (2011)
  77. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR. J Virol 83 10892-10907 (2009)
  78. Large-scale conformational sampling of proteins using temperature-accelerated molecular dynamics. Abrams CF, Vanden-Eijnden E. Proc Natl Acad Sci U S A 107 4961-4966 (2010)
  79. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DF, Saksena N, Wang B, Sonza S, Wesselingh SL, Karlsson I, Fenyo EM, Gabuzda D, Cunningham AL, Gorry PR. Retrovirology 4 89 (2007)
  80. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, Burton DR, Zwick MB, Wilson IA. J Virol 83 8451-8462 (2009)
  81. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, Scott JK. PLoS One 6 e16857 (2011)
  82. Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Mao Y, Wang L, Gu C, Herschhorn A, Désormeaux A, Finzi A, Xiang SH, Sodroski JG. Proc Natl Acad Sci U S A 110 12438-12443 (2013)
  83. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Diskin R, Marcovecchio PM, Bjorkman PJ. Nat Struct Mol Biol 17 608-613 (2010)
  84. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. Blish CA, Nguyen MA, Overbaugh J. PLoS Med 5 e9 (2008)
  85. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. Go EP, Chang Q, Liao HX, Sutherland LL, Alam SM, Haynes BF, Desaire H. J Proteome Res 8 4231-4242 (2009)
  86. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB. Sci Transl Med 4 142ra96 (2012)
  87. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. Inci F, Tokel O, Wang S, Gurkan UA, Tasoglu S, Kuritzkes DR, Demirci U. ACS Nano 7 4733-4745 (2013)
  88. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham PR. Retrovirology 5 5 (2008)
  89. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Yoon H, Macke J, West AP, Foley B, Bjorkman PJ, Korber B, Yusim K. Nucleic Acids Res 43 W213-9 (2015)
  90. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H. J Virol 85 6986-6995 (2011)
  91. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR. J Virol 86 5844-5856 (2012)
  92. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC. Virology 385 505-520 (2009)
  93. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D. Virology 367 222-234 (2007)
  94. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH, Gupta A, Bai T, Murphy VJ, Anders RF, Foley M, Nuttall SD. Structure 15 1452-1466 (2007)
  95. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Kim M, Sun ZY, Rand KD, Shi X, Song L, Cheng Y, Fahmy AF, Majumdar S, Ofek G, Yang Y, Kwong PD, Wang JH, Engen JR, Wagner G, Reinherz EL. Nat Struct Mol Biol 18 1235-1243 (2011)
  96. Congress Antibody-based HIV-1 vaccines: recent developments and future directions. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J, Working Group convened by the Global HIV Vaccine Enterprise. PLoS Med 4 e348 (2007)
  97. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, Cohen MS, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B. PLoS Comput Biol 6 e1000955 (2010)
  98. Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Liu Q, Acharya P, Dolan MA, Zhang P, Guzzo C, Lu J, Kwon A, Gururani D, Miao H, Bylund T, Chuang GY, Druz A, Zhou T, Rice WJ, Wigge C, Carragher B, Potter CS, Kwong PD, Lusso P. Nat Struct Mol Biol 24 370-378 (2017)
  99. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW. PLoS Pathog 3 e117 (2007)
  100. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT. Proc Natl Acad Sci U S A 111 E738-47 (2014)
  101. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. J Virol 82 7369-7378 (2008)
  102. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, Wormald MR, Finn MG, Burton DR, Wilson IA, Davis BG. Proc Natl Acad Sci U S A 107 17107-17112 (2010)
  103. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. J Mol Biol 375 969-978 (2008)
  104. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW. Virology 401 236-247 (2010)
  105. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Schommers P, Gruell H, Abernathy ME, Tran MK, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MM, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman PJ, Klein F. Cell 180 471-489.e22 (2020)
  106. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. McGuire AT, Glenn JA, Lippy A, Stamatatos L. J Virol 88 2645-2657 (2014)
  107. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y, Wilson IA, Zhu J, Shao Y. Immunity 44 939-950 (2016)
  108. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. Kong L, Sheppard NC, Stewart-Jones GBE, Robson CL, Chen H, Xu X, Krashias G, Bonomelli C, Scanlan CN, Kwong PD, Jeffs SA, Jones IM, Sattentau QJ. J Mol Biol 403 131-147 (2010)
  109. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. Xiang SH, Finzi A, Pacheco B, Alexander K, Yuan W, Rizzuto C, Huang CC, Kwong PD, Sodroski J. J Virol 84 3147-3161 (2010)
  110. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, Nieva JL, Pai EF. J Virol 84 4136-4147 (2010)
  111. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A, DiMarcello F, Marchi S, van der Ende A, Aricó B, Savino S, Scarselli M, Comanducci M, Rappuoli R, Giuliani MM, Pizza M. Infect Immun 79 970-981 (2011)
  112. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM. J Virol 83 1240-1259 (2009)
  113. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, Singer BB, Lucka L, Wormald MR, Wentworth P, Zitzmann N, Rudd PM, Burton DR, Dwek RA. J Mol Biol 372 16-22 (2007)
  114. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Chuang GY, Geng H, Pancera M, Xu K, Cheng C, Acharya P, Chambers M, Druz A, Tsybovsky Y, Wanninger TG, Yang Y, Doria-Rose NA, Georgiev IS, Gorman J, Joyce MG, O'Dell S, Zhou T, McDermott AB, Mascola JR, Kwong PD. J Virol 91 e02268-16 (2017)
  115. Appreciating HIV type 1 diversity: subtype differences in Env. Lynch RM, Shen T, Gnanakaran S, Derdeyn CA. AIDS Res Hum Retroviruses 25 237-248 (2009)
  116. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, Durso RJ, Parsons TF, Maddon PJ, Moore JP, Olson WC. Vaccine 27 5120-5132 (2009)
  117. AIDS/HIV. A boost for HIV vaccine design. Burton DR, Weiss RA. Science 329 770-773 (2010)
  118. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B. Cell Host Microbe 25 59-72.e8 (2019)
  119. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, Jankovic M, Corti D, Lanzavecchia A, Nussenzweig MC. J Exp Med 207 1995-2002 (2010)
  120. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. Chuang GY, Acharya P, Schmidt SD, Yang Y, Louder MK, Zhou T, Kwon YD, Pancera M, Bailer RT, Doria-Rose NA, Nussenzweig MC, Mascola JR, Kwong PD, Georgiev IS. J Virol 87 10047-10058 (2013)
  121. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. Doores KJ, Fulton Z, Huber M, Wilson IA, Burton DR. J Virol 84 10690-10699 (2010)
  122. Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Wang H, Barnes CO, Yang Z, Nussenzweig MC, Bjorkman PJ. Cell Host Microbe 24 579-592.e4 (2018)
  123. Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, Hoiseth SK, Jacob J, Lin SL, Malakian K, McNeil LK, Mininni T, Moy F, Murphy E, Novikova E, Sigethy S, Wen Y, Zlotnick GW, Tsao DH. J Biol Chem 284 8738-8746 (2009)
  124. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, Allen S, Robinson JE, Gnanakaran S, Derdeyn CA. J Virol 85 905-915 (2011)
  125. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. Duenas-Decamp MJ, Peters P, Burton D, Clapham PR. J Virol 82 5807-5814 (2008)
  126. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. Mörner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, O'Dell S, Dey B, Kwong PD, Voss G, Thorstensson R, Mascola JR, Wyatt RT, Karlsson Hedestam GB. J Virol 83 540-551 (2009)
  127. Role of spike protein endodomains in regulating coronavirus entry. Shulla A, Gallagher T. J Biol Chem 284 32725-32734 (2009)
  128. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Huang KH, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, Main J, Muir D, Weber JN, Frater AJ, Phillips RE, Pybus OG, Goulder PJ, McClure MO, Cooke GS, Klenerman P. Nat Commun 1 102 (2010)
  129. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Williams WB, Zhang J, Jiang C, Nicely NI, Fera D, Luo K, Moody MA, Liao HX, Alam SM, Kepler TB, Ramesh A, Wiehe K, Holland JA, Bradley T, Vandergrift N, Saunders KO, Parks R, Foulger A, Xia SM, Bonsignori M, Montefiori DC, Louder M, Eaton A, Santra S, Scearce R, Sutherland L, Newman A, Bouton-Verville H, Bowman C, Bomze H, Gao F, Marshall DJ, Whitesides JF, Nie X, Kelsoe G, Reed SG, Fox CB, Clary K, Koutsoukos M, Franco D, Mascola JR, Harrison SC, Haynes BF, Verkoczy L. Nat Commun 8 1732 (2017)
  130. Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. Guttman M, Kahn M, Garcia NK, Hu SL, Lee KK. J Virol 86 8750-8764 (2012)
  131. Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, Rubinstein ND, Pupko T, Gershoni JM. Proteins 68 294-304 (2007)
  132. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT. J Biol Chem 287 5673-5686 (2012)
  133. Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Wu SR, Löving R, Lindqvist B, Hebert H, Koeck PJ, Sjöberg M, Garoff H. Proc Natl Acad Sci U S A 107 18844-18849 (2010)
  134. Functional analysis of the transmembrane domain in paramyxovirus F protein-mediated membrane fusion. Bissonnette ML, Donald JE, DeGrado WF, Jardetzky TS, Lamb RA. J Mol Biol 386 14-36 (2009)
  135. Efficient on-chip isolation of HIV subtypes. Wang S, Esfahani M, Gurkan UA, Inci F, Kuritzkes DR, Demirci U. Lab Chip 12 1508-1515 (2012)
  136. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. Hu G, Liu J, Taylor KA, Roux KH. J Virol 85 2741-2750 (2011)
  137. Automated detection of conformational epitopes using phage display Peptide sequences. Negi SS, Braun W. Bioinform Biol Insights 3 71-81 (2009)
  138. Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, Cocco N, Kachare M, Massi E, David KB, Cupo A, Marozsan AJ, Olson WC, Ward AB, Wilson IA, Sanders RW, Moore JP. J Biol Chem 287 24239-24254 (2012)
  139. Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping. Scarabelli G, Morra G, Colombo G. Biophys J 98 1966-1975 (2010)
  140. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. Désormeaux A, Coutu M, Medjahed H, Pacheco B, Herschhorn A, Gu C, Xiang SH, Mao Y, Sodroski J, Finzi A. J Virol 87 2549-2562 (2013)
  141. Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D, Han B, Sun W, Wu H, Wang X, Zhang L. J Biol Chem 286 14531-14541 (2011)
  142. Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. Brown RJ, Peters PJ, Caron C, Gonzalez-Perez MP, Stones L, Ankghuambom C, Pondei K, McClure CP, Alemnji G, Taylor S, Sharp PM, Clapham PR, Ball JK. J Virol 85 6024-6037 (2011)
  143. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Virology 381 251-260 (2008)
  144. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL. J Immunol 196 3064-3078 (2016)
  145. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, Maruyama T, Bewley CA, Bowdish K, Clore GM, Dawson PE, Frederickson S, Mage RG, Richman DD, Burton DR, Zwick MB. Virology 377 170-183 (2008)
  146. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. Bryson S, Julien JP, Hynes RC, Pai EF. J Virol 83 11862-11875 (2009)
  147. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, Hoxie JA, Robinson JE, Moore PL, Binley JM. Virology 377 364-378 (2008)
  148. CD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infection. Cagigi A, Du L, Dang LV, Grutzmeier S, Atlas A, Chiodi F, Pan-Hammarström Q, Nilsson A. PLoS One 4 e5427 (2009)
  149. Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. Mata-Fink J, Kriegsman B, Yu HX, Zhu H, Hanson MC, Irvine DJ, Wittrup KD. J Mol Biol 425 444-456 (2013)
  150. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, Zhang R, Sutherland LL, Scearce RM, Bowman CM, Stolarchuk C, Lloyd KE, Parks R, Eaton A, Foulger A, Nie X, Karim SSA, Barnett S, Kelsoe G, Kepler TB, Alam SM, Montefiori DC, Moody MA, Liao HX, Morris L, Santra S, Harrison SC, Haynes BF. Cell Rep 14 43-54 (2016)
  151. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA. PLoS Pathog 9 e1003173 (2013)
  152. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L. J Virol 85 9039-9050 (2011)
  153. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ. J Virol 83 5077-5086 (2009)
  154. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P, Li Y, Seder R, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB. J Virol 84 1683-1695 (2010)
  155. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. Gray ES, Moore PL, Pantophlet RA, Morris L. J Virol 81 10769-10776 (2007)
  156. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Sanders RW, van Anken E, Nabatov AA, Liscaljet IM, Bontjer I, Eggink D, Melchers M, Busser E, Dankers MM, Groot F, Braakman I, Berkhout B, Paxton WA. Retrovirology 5 10 (2008)
  157. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Montefiori DC, Schief WR, Sattentau QJ. J Virol 87 10163-10172 (2013)
  158. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR. J Virol 85 4578-4585 (2011)
  159. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T. PLoS One 7 e33298 (2012)
  160. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW. J Virol 83 368-383 (2009)
  161. HIV-1 Entry, Inhibitors, and Resistance. Lobritz MA, Ratcliff AN, Arts EJ. Viruses 2 1069-1105 (2010)
  162. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD. J Virol 85 2524-2535 (2011)
  163. Genome-scale detection of positive selection in nine primates predicts human-virus evolutionary conflicts. van der Lee R, Wiel L, van Dam TJP, Huynen MA. Nucleic Acids Res 45 10634-10648 (2017)
  164. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F, Berman PW. J Virol 84 11200-11209 (2010)
  165. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. Sagar M, Akiyama H, Etemad B, Ramirez N, Freitas I, Gummuluru S. J Infect Dis 205 1248-1257 (2012)
  166. A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. Sethi A, Tian J, Derdeyn CA, Korber B, Gnanakaran S. PLoS Comput Biol 9 e1003046 (2013)
  167. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. Finzi A, Pacheco B, Zeng X, Kwon YD, Kwong PD, Sodroski J. J Virol Methods 168 155-161 (2010)
  168. Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. Dunfee RL, Thomas ER, Gabuzda D. Retrovirology 6 69 (2009)
  169. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, Grisson RD, Wood C, Zhang H, Kankasa C, Amara RR, Else JG, Novembre FJ, Montefiori DC, Ruprecht RM. J Virol 83 1422-1432 (2009)
  170. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M. J Virol 84 4311-4320 (2010)
  171. A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC. PLoS Pathog 11 e1005238 (2015)
  172. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. Trends Mol Med 17 108-116 (2011)
  173. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. van den Kerkhof TL, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LW, Boeser-Nunnink BD, Heringa J, Schuitemaker H, Sanders RW. Retrovirology 10 102 (2013)
  174. Progress in the rational design of an AIDS vaccine. Nabel GJ, Kwong PD, Mascola JR. Philos Trans R Soc Lond B Biol Sci 366 2759-2765 (2011)
  175. Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 ΔCFI shows variability in the V1 and V2 regions. Go EP, Zhang Y, Menon S, Desaire H. J Proteome Res 10 578-591 (2011)
  176. Basic research in HIV vaccinology is hampered by reductionist thinking. Van Regenmortel MH. Front Immunol 3 194 (2012)
  177. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Dey AK, David KB, Lu M, Moore JP. Virology 385 275-281 (2009)
  178. Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1. Koh WW, Steffensen S, Gonzalez-Pajuelo M, Hoorelbeke B, Gorlani A, Szynol A, Forsman A, Aasa-Chapman MM, de Haard H, Verrips T, Weiss RA. J Biol Chem 285 19116-19124 (2010)
  179. Human herpesvirus 6 glycoprotein complex formation is required for folding and trafficking of the gH/gL/gQ1/gQ2 complex and its cellular receptor binding. Tang H, Hayashi M, Maeki T, Yamanishi K, Mori Y. J Virol 85 11121-11130 (2011)
  180. Morphology and ultrastructure of retrovirus particles. Zhang W, Cao S, Martin JL, Mueller JD, Mansky LM. AIMS Biophys 2 343-369 (2015)
  181. Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. Li H, Xu CF, Blais S, Wan Q, Zhang HT, Landry SJ, Hioe CE. J Immunol 182 6369-6378 (2009)
  182. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P. J Virol 87 1137-1149 (2013)
  183. A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. Guttman M, Lee KK. J Virol 87 11462-11475 (2013)
  184. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D. J Immunol 191 3179-3185 (2013)
  185. Design, expression, and characterization of a multivalent, combination HIV microbicide. Sexton A, Harman S, Shattock RJ, Ma JK. FASEB J 23 3590-3600 (2009)
  186. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Chen H, Xu X, Jones IM. Retrovirology 4 33 (2007)
  187. Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. Kong L, Huang CC, Coales SJ, Molnar KS, Skinner J, Hamuro Y, Kwong PD. J Virol 84 10311-10321 (2010)
  188. Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S, Nabel GJ, Mascola JR. Virology 380 285-295 (2008)
  189. Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Li S, Wang H, Peng B, Zhang M, Zhang D, Hou S, Guo Y, Ding J. Proc Natl Acad Sci U S A 106 4349-4354 (2009)
  190. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT. J Virol 88 14002-14016 (2014)
  191. Potential neutralizing antibodies discovered for novel corona virus using machine learning. Magar R, Yadav P, Barati Farimani A. Sci Rep 11 5261 (2021)
  192. Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. Humes D, Overbaugh J. J Virol 85 4409-4420 (2011)
  193. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. Selvarajah S, Puffer BA, Lee FH, Zhu P, Li Y, Wyatt R, Roux KH, Doms RW, Burton DR. AIDS Res Hum Retroviruses 24 301-314 (2008)
  194. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Visciano ML, Tuen M, Gorny MK, Hioe CE. Virology 372 409-420 (2008)
  195. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, Dimitrov DS. Front Microbiol 3 277 (2012)
  196. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. Joyce MG, Kanekiyo M, Xu L, Biertümpfel C, Boyington JC, Moquin S, Shi W, Wu X, Yang Y, Yang ZY, Zhang B, Zheng A, Zhou T, Zhu J, Mascola JR, Kwong PD, Nabel GJ. J Virol 87 2294-2306 (2013)
  197. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. Xie H, Ng D, Savinov SN, Dey B, Kwong PD, Wyatt R, Smith AB, Hendrickson WA. J Med Chem 50 4898-4908 (2007)
  198. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection. Ringe R, Thakar M, Bhattacharya J. Retrovirology 7 76 (2010)
  199. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site. Wielens J, Headey SJ, Jeevarajah D, Rhodes DI, Deadman J, Chalmers DK, Scanlon MJ, Parker MW. FEBS Lett 584 1455-1462 (2010)
  200. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. Hijazi K, Wang Y, Scala C, Jeffs S, Longstaff C, Stieh D, Haggarty B, Vanham G, Schols D, Balzarini J, Jones IM, Hoxie J, Shattock R, Kelly CG. PLoS One 6 e28307 (2011)
  201. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. Bhattacharyya S, Rajan RE, Swarupa Y, Rathore U, Verma A, Udaykumar R, Varadarajan R. J Biol Chem 285 27100-27110 (2010)
  202. GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Wen M, Arora R, Wang H, Liu L, Kimata JT, Zhou P. Retrovirology 7 79 (2010)
  203. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Kumar R, Tuen M, Li H, Tse DB, Hioe CE. Vaccine 29 9064-9074 (2011)
  204. Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. Kong L, Sattentau QJ. J AIDS Clin Res S8 3 (2012)
  205. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Nandi A, Lavine CL, Wang P, Lipchina I, Goepfert PA, Shaw GM, Tomaras GD, Montefiori DC, Haynes BF, Easterbrook P, Robinson JE, Sodroski JG, Yang X, NIAID Center for HIV/AIDS Vaccine Immunology. Virology 396 339-348 (2010)
  206. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, Morris MK, Nishiyama Y, Ghosh D, Kumar A, Gao F, Hanson CV, Paul S. AIDS 24 875-884 (2010)
  207. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. Guenaga J, Wyatt RT. PLoS Pathog 8 e1002806 (2012)
  208. Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. Leysath CE, Monzingo AF, Maynard JA, Barnett J, Georgiou G, Iverson BL, Robertus JD. J Mol Biol 387 680-693 (2009)
  209. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel MP, Despres P, Tangy F, Dalba C, Klatzmann D. Vaccine 27 5772-5780 (2009)
  210. HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W. PLoS Med 11 e1001616 (2014)
  211. Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ. AIDS Res Hum Retroviruses 28 206-214 (2012)
  212. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response. Dubrovskaya V, Guenaga J, de Val N, Wilson R, Feng Y, Movsesyan A, Karlsson Hedestam GB, Ward AB, Wyatt RT. PLoS Pathog 13 e1006614 (2017)
  213. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, Cranage M, Malcolm RK, Shattock RJ, Woolfson AD. Vaccine 27 6791-6798 (2009)
  214. Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction. Hinz A, Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W. PLoS One 5 e10482 (2010)
  215. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. Humbert M, Rasmussen RA, Ong H, Kaiser FM, Hu SL, Ruprecht RM. PLoS One 3 e3937 (2008)
  216. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK. J Virol 85 10529-10541 (2011)
  217. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, Sinangil F, Berman PW. J Virol 83 7728-7738 (2009)
  218. R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. Tasca S, Ho SH, Cheng-Mayer C. J Virol 82 7089-7099 (2008)
  219. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. Mufhandu HT, Gray ES, Madiga MC, Tumba N, Alexandre KB, Khoza T, Wibmer CK, Moore PL, Morris L, Khati M. J Virol 86 4989-4999 (2012)
  220. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. Nolan KM, Del Prete GQ, Jordan AP, Haggarty B, Romano J, Leslie GJ, Hoxie JA. J Virol 83 3798-3809 (2009)
  221. Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein. Buffalo CZ, Bahn-Suh AJ, Hirakis SP, Biswas T, Amaro RE, Nizet V, Ghosh P. Nat Microbiol 1 16155 (2016)
  222. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. Yu B, Fonseca DP, O'Rourke SM, Berman PW. J Virol 84 1513-1526 (2010)
  223. Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanism. Chi SW, Maeng CY, Kim SJ, Oh MS, Ryu CJ, Kim SJ, Han KH, Hong HJ, Ryu SE. Proc Natl Acad Sci U S A 104 9230-9235 (2007)
  224. Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Schiffner T, de Val N, Russell RA, de Taeye SW, de la Peña AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau QJ. J Virol 90 813-828 (2016)
  225. Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. Acharya P, Luongo TS, Louder MK, McKee K, Yang Y, Kwon YD, Mascola JR, Kessler P, Martin L, Kwong PD. Structure 21 1018-1029 (2013)
  226. The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. Hufton SE, Risley P, Ball CR, Major D, Engelhardt OG, Poole S. PLoS One 9 e103294 (2014)
  227. 3D visualization of HIV virions by cryoelectron tomography. Liu J, Wright ER, Winkler H. Methods Enzymol 483 267-290 (2010)
  228. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens. Chen W, Streaker ED, Russ DE, Feng Y, Prabakaran P, Dimitrov DS. Biochem Biophys Res Commun 417 1164-1169 (2012)
  229. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JP, Hahn BH, Kwong PD, Robinson JE, Shaw GM. J Virol 86 12115-12128 (2012)
  230. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC. PLoS Pathog 14 e1007431 (2018)
  231. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. Duenas-Decamp MJ, Clapham PR. J Virol 84 9608-9612 (2010)
  232. High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. Wang Y, Sundling C, Wilson R, O'Dell S, Chen Y, Dai K, Phad GE, Zhu J, Xiao Y, Mascola JR, Karlsson Hedestam GB, Wyatt RT, Li Y. J Immunol 196 3729-3743 (2016)
  233. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS. PLoS One 7 e44241 (2012)
  234. Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Hraber P, Korber B, Wagh K, Giorgi EE, Bhattacharya T, Gnanakaran S, Lapedes AS, Learn GH, Kreider EF, Li Y, Shaw GM, Hahn BH, Montefiori DC, Alam SM, Bonsignori M, Moody MA, Liao HX, Gao F, Haynes BF. Viruses 7 5443-5475 (2015)
  235. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Alexandre KB, Moore PL, Nonyane M, Gray ES, Ranchobe N, Chakauya E, McMahon JB, O'Keefe BR, Chikwamba R, Morris L. Virology 446 66-76 (2013)
  236. Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F, Limoli K, Wrin T, Berman PW. J Virol 86 12105-12114 (2012)
  237. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Weiss RA. Clin Exp Immunol 152 201-210 (2008)
  238. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW. J Biol Chem 285 36456-36470 (2010)
  239. epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES, Perez LG, Haynes BF, Liao HX, Labranche CC, Korber BT, Montefiori DC. J Virol 85 9286-9299 (2011)
  240. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Ahmed FK, Clark BE, Burton DR, Pantophlet R. Vaccine 30 922-930 (2012)
  241. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. Craig RB, Summa CM, Corti M, Pincus SH. PLoS One 7 e46778 (2012)
  242. Cross-reactive broadly neutralizing antibodies: timing is everything. Euler Z, Schuitemaker H. Front Immunol 3 215 (2012)
  243. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization. Navis M, Tran K, Bale S, Phad GE, Guenaga J, Wilson R, Soldemo M, McKee K, Sundling C, Mascola J, Li Y, Wyatt RT, Karlsson Hedestam GB. PLoS Pathog 10 e1004337 (2014)
  244. Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. Hong B, Song XT, Rollins L, Berry L, Huang XF, Chen SY. J Clin Invest 121 739-751 (2011)
  245. Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting. Li X, Grant OC, Ito K, Wallace A, Wang S, Zhao P, Wells L, Lu S, Woods RJ, Sharp JS. Biochemistry 56 957-970 (2017)
  246. Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. Stanfield RL, Berndsen ZT, Huang R, Sok D, Warner G, Torres JL, Burton DR, Ward AB, Ward AB, Wilson IA, Smider VV. Sci Adv 6 eaba0468 (2020)
  247. Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies. Bhattacharyya S, Singh P, Rathore U, Purwar M, Wagner D, Arendt H, DeStefano J, LaBranche CC, Montefiori DC, Phogat S, Varadarajan R. J Biol Chem 288 9815-9825 (2013)
  248. Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. Raska M, Czernekova L, Moldoveanu Z, Zachova K, Elliott MC, Novak Z, Hall S, Hoelscher M, Maboko L, Brown R, Smith PD, Mestecky J, Novak J. AIDS Res Ther 11 23 (2014)
  249. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong XP, Lu S, Clapham PR. J Virol 87 187-198 (2013)
  250. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. Acharya P, Luongo TS, Georgiev IS, Matz J, Schmidt SD, Louder MK, Kessler P, Yang Y, McKee K, O'Dell S, Chen L, Baty D, Chames P, Martin L, Mascola JR, Kwong PD. J Virol 87 10173-10181 (2013)
  251. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP. PLoS One 9 e85349 (2014)
  252. Recapitulating Cross-Species Transmission of Simian Immunodeficiency Virus SIVcpz to Humans by Using Humanized BLT Mice. Yuan Z, Kang G, Ma F, Lu W, Fan W, Fennessey CM, Keele BF, Li Q. J Virol 90 7728-7739 (2016)
  253. Some binding-related drug properties are dependent on thermodynamic signature. Schön A, Madani N, Smith AB, Lalonde JM, Freire E. Chem Biol Drug Des 77 161-165 (2011)
  254. Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. Murin CD, Bruhn JF, Bornholdt ZA, Copps J, Stanfield R, Ward AB. Cell Rep 24 2723-2732.e4 (2018)
  255. Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. Rathinakumar R, Dutta M, Zhu P, Johnson WE, Roux KH. J Virol 86 1820-1831 (2012)
  256. Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. Barroso H, Borrego P, Bártolo I, Marcelino JM, Família C, Quintas A, Taveira N. PLoS One 6 e14548 (2011)
  257. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. Grupping K, Selhorst P, Michiels J, Vereecken K, Heyndrickx L, Kessler P, Vanham G, Martin L, Ariën KK. Retrovirology 9 36 (2012)
  258. Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa. McKinley SA, Chen A, Shi F, Wang S, Mucha PJ, Forest MG, Lai SK. PLoS One 9 e100598 (2014)
  259. Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis. Liu Y, Schön A, Freire E. Chem Biol Drug Des 81 72-78 (2013)
  260. Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry. Wang L, Qin Y, Ilchenko S, Bohon J, Shi W, Cho MW, Takamoto K, Chance MR. Biochemistry 49 9032-9045 (2010)
  261. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB. PLoS One 8 e72054 (2013)
  262. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Emileh A, Tuzer F, Yeh H, Umashankara M, Moreira DR, Lalonde JM, Bewley CA, Abrams CF, Chaiken IM. Biochemistry 52 2245-2261 (2013)
  263. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. Burioni R, Mancini N, De Marco D, Clementi N, Perotti M, Nitti G, Sassi M, Canducci F, Shvela K, Bagnarelli P, Mascola JR, Clementi M. PLoS One 3 e3423 (2008)
  264. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Spurrier B, Sampson JM, Totrov M, Li H, O'Neal T, Williams C, Robinson J, Gorny MK, Zolla-Pazner S, Kong XP. Structure 19 691-699 (2011)
  265. Absolute quantitation of glycosylation site occupancy using isotopically labeled standards and LC-MS. Zhu Z, Go EP, Desaire H. J Am Soc Mass Spectrom 25 1012-1017 (2014)
  266. Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity. Ringe R, Bhattacharya J. PLoS One 7 e37157 (2012)
  267. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. Liang Y, Guttman M, Williams JA, Verkerke H, Alvarado D, Hu SL, Lee KK. J Virol 90 9224-9236 (2016)
  268. Crystal structure of a bony fish beta2-microglobulin: insights into the evolutionary origin of immunoglobulin superfamily constant molecules. Chen W, Gao F, Chu F, Zhang J, Gao GF, Xia C. J Biol Chem 285 22505-22512 (2010)
  269. Exploiting glycan topography for computational design of Env glycoprotein antigenicity. Yu WH, Zhao P, Draghi M, Arevalo C, Karsten CB, Suscovich TJ, Gunn B, Streeck H, Brass AL, Tiemeyer M, Seaman M, Mascola JR, Wells L, Lauffenburger DA, Alter G. PLoS Comput Biol 14 e1006093 (2018)
  270. HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. Eggink D, de Taeye SW, Bontjer I, Klasse PJ, Langedijk JPM, Berkhout B, Sanders RW. J Virol 90 10587-10599 (2016)
  271. HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ. Retrovirology 13 48 (2016)
  272. Comment HIV/AIDS: allied responses. Mascola JR. Nature 449 29-30 (2007)
  273. Human 4F5 single-chain Fv antibody recognizing a conserved HA1 epitope has broad neutralizing potency against H5N1 influenza A viruses of different clades. Zhang X, Qi X, Zhang Q, Zeng X, Shi Z, Jin Q, Zhan F, Xu Y, Liu Z, Feng Z, Jiao Y. Antiviral Res 99 91-99 (2013)
  274. Importance of V3 loop flexibility and net charge in the context of co-receptor recognition. A molecular dynamics study on HIV gp120. Chandramouli B, Chillemi G, Abbate I, Capobianchi MR, Rozera G, Desideri A. J Biomol Struct Dyn 29 879-891 (2012)
  275. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Donnelly L, Curran RM, Tregoning JS, McKay PF, Cole T, Morrow RJ, Kett VL, Andrews GP, Woolfson AD, Malcolm RK, Shattock RJ. Vaccine 29 4512-4520 (2011)
  276. Labeling Cell Surface GPIs and GPI-Anchored Proteins through Metabolic Engineering with Artificial Inositol Derivatives. Lu L, Gao J, Guo Z. Angew Chem Int Ed Engl 54 9679-9682 (2015)
  277. Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. Zhang MY, Borges AR, Ptak RG, Wang Y, Dimitrov AS, Alam SM, Wieczorek L, Bouma P, Fouts T, Jiang S, Polonis VR, Haynes BF, Quinnan GV, Montefiori DC, Dimitrov DS. MAbs 2 266-274 (2010)
  278. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, Barnett SW. PLoS One 8 e76139 (2013)
  279. Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA. J Mol Biol 414 460-476 (2011)
  280. The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop. Wood NT, Fadda E, Davis R, Grant OC, Martin JC, Woods RJ, Travers SA. PLoS One 8 e80301 (2013)
  281. Tunable Fano-Resonant Metasurfaces on a Disposable Plastic-Template for Multimodal and Multiplex Biosensing. Ahmed R, Ozen MO, Karaaslan MG, Prator CA, Thanh C, Kumar S, Torres L, Iyer N, Munter S, Southern S, Henrich TJ, Inci F, Demirci U. Adv Mater 32 e1907160 (2020)
  282. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. Mikell I, Stamatatos L. PLoS One 7 e49610 (2012)
  283. News HIV-1: from escapism to conservatism. Hanke T, McMichael AJ. Eur J Immunol 41 3390-3393 (2011)
  284. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins. Wang P, Yang X. J Virol 84 7114-7123 (2010)
  285. Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. Zhao C, Gunawardana M, Villinger F, Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ, Bohorov O, Smith TJ, Anderson DJ, Moss JA. Antimicrob Agents Chemother 61 e02465-16 (2017)
  286. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. Narayan KM, Agrawal N, Du SX, Muranaka JE, Bauer K, Leaman DP, Phung P, Limoli K, Chen H, Boenig RI, Wrin T, Zwick MB, Whalen RG. PLoS One 8 e52732 (2013)
  287. Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. Liang Y, Guttman M, Davenport TM, Hu SL, Lee KK. Biochemistry 55 2197-2213 (2016)
  288. Probing the effect of force on HIV-1 receptor CD4. Perez-Jimenez R, Alonso-Caballero A, Berkovich R, Franco D, Chen MW, Richard P, Badilla CL, Fernandez JM. ACS Nano 8 10313-10320 (2014)
  289. Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange. Cerutti N, Mendelow BV, Napier GB, Papathanasopoulos MA, Killick M, Khati M, Stevens W, Capovilla A. J Biol Chem 285 25743-25752 (2010)
  290. The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. Amadori C, van der Velden YU, Bonnard D, Orlov I, van Bel N, Le Rouzic E, Miralles L, Brias J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Mayr L, Moreau F, García F, Gatell J, Zamborlini A, Emiliani S, Ruff M, Klaholz BP, Moog C, Berkhout B, Plana M, Benarous R. Retrovirology 14 50 (2017)
  291. Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model. DeLeon O, Hodis H, O'Malley Y, Johnson J, Salimi H, Zhai Y, Winter E, Remec C, Eichelberger N, Van Cleave B, Puliadi R, Harrington RD, Stapleton JT, Haim H. PLoS Biol 15 e2001549 (2017)
  292. Behavior of ligand binding assays with crowded surfaces: Molecular model of antigen capture by antibody-conjugated nanoparticles. Malaspina DC, Longo G, Szleifer I. PLoS One 12 e0185518 (2017)
  293. Discrete partitioning of HIV-1 Env forms revealed by viral capture. Stieh DJ, King DF, Klein K, Aldon Y, McKay PF, Shattock RJ. Retrovirology 12 81 (2015)
  294. Lipidation of intact proteins produces highly immunogenic vaccine candidates. Zeng W, Eriksson EM, Lew A, Jackson DC. Mol Immunol 48 490-496 (2011)
  295. N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03. Wang W, Zirkle B, Nie J, Ma J, Gao K, Chen XS, Huang W, Kong W, Wang Y. J Acquir Immune Defic Syndr 69 270-277 (2015)
  296. Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors. Danial M, Root MJ, Klok HA. Biomacromolecules 13 1438-1447 (2012)
  297. A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. van Montfort T, Melchers M, Isik G, Menis S, Huang PS, Matthews K, Michael E, Berkhout B, Schief WR, Moore JP, Sanders RW. J Biol Chem 286 22250-22261 (2011)
  298. Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Canducci F, Marinozzi MC, Sampaolo M, Berrè S, Bagnarelli P, Degano M, Gallotta G, Mazzi B, Lemey P, Burioni R, Clementi M. Retrovirology 6 4 (2009)
  299. Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, Montefiori DC, Wang C, Cho MW. Virology 462-463 363-376 (2014)
  300. Enhancement and induction of HIV-1 infection through an assembled peptide derived from the CD4 binding site of gp120. Groß A, Rödel K, Kneidl B, Donhauser N, Mössl M, Lump E, Münch J, Schmidt B, Eichler J. Chembiochem 16 446-454 (2015)
  301. Epitope mapping of metuximab on CD147 using phage display and molecular docking. He B, Mao C, Ru B, Han H, Zhou P, Huang J. Comput Math Methods Med 2013 983829 (2013)
  302. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Karlsson Hedestam GB, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME. JCI Insight 3 97018 (2018)
  303. HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor. Chain BM, Noursadeghi M, Gardener M, Tsang J, Wright E. Vaccine 26 5752-5759 (2008)
  304. Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units. Löving R, Sjöberg M, Wu SR, Binley JM, Garoff H. J Virol 87 7000-7007 (2013)
  305. New templates for HIV-1 antibody-based vaccine design. Sattentau QJ, McMichael AJ. F1000 Biol Rep 2 60 (2010)
  306. One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. Li W, Wu Y, Kong D, Yang H, Wang Y, Shao J, Feng Y, Chen W, Ma L, Ying T, Dimitrov DS. Sci Rep 7 9130 (2017)
  307. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. Liu L, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT, Zhou P. J Virol 85 8467-8476 (2011)
  308. Prediction of HIV-1 entry inhibitors neomycin-arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure. Berchanski A, Lapidot A. Biochim Biophys Acta 1768 2107-2119 (2007)
  309. News Protein structures: Structures of desire. Bhattacharya A. Nature 459 24-27 (2009)
  310. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication. Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L. Retrovirology 12 54 (2015)
  311. Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120. Korkut A, Hendrickson WA. PLoS One 7 e52170 (2012)
  312. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. Berkower I, Patel C, Ni Y, Virnik K, Xiang Z, Spadaccini A. Virology 377 330-338 (2008)
  313. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, Symersky J, Boivin S, Sienczyk M, Salas M, Hanson CV, Paul S. J Biol Chem 284 30627-30642 (2009)
  314. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. Kelker HC, Itri VR, Valentine FT. PLoS One 5 e8555 (2010)
  315. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, Morris MK, Hara M, Liao G, Massey RJ, Hanson CV, Paul S. J Immunol 189 5367-5381 (2012)
  316. Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Arnold P, Himmels P, Weiß S, Decker TM, Markl J, Gatterdam V, Tampé R, Bartholomäus P, Dietrich U, Dürr R. Retrovirology 11 42 (2014)
  317. Backbone flexibility of CDR3 and immune recognition of antigens. Haidar JN, Zhu W, Lypowy J, Pierce BG, Bari A, Persaud K, Luna X, Snavely M, Ludwig D, Weng Z. J Mol Biol 426 1583-1599 (2014)
  318. Correlates of antibody-mediated protection against HIV infection. Sattentau Q. Curr Opin HIV AIDS 3 368-374 (2008)
  319. Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus. Watkins JD, Diaz-Rodriguez J, Siddappa NB, Corti D, Ruprecht RM. J Virol 85 12811-12814 (2011)
  320. Global structure of HIV-1 neutralizing antibody IgG1 b12 is asymmetric. Ashish, Solanki AK, Boone CD, Krueger JK. Biochem Biophys Res Commun 391 947-951 (2010)
  321. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. Zhou N, Fan L, Ho HT, Nowicka-Sans B, Sun Y, Zhu Y, Hu Y, McAuliffe B, Rose B, Fang H, Wang T, Kadow J, Krystal M, Alexander L, Colonno R, Lin PF. Virology 402 256-261 (2010)
  322. NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences. Chuang GY, Liou D, Kwong PD, Georgiev IS. Nucleic Acids Res 42 W64-71 (2014)
  323. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. Chen Y, Wilson R, O'Dell S, Guenaga J, Feng Y, Tran K, Chiang CI, Arendt HE, DeStefano J, Mascola JR, Wyatt RT, Li Y. J Immunol 197 3982-3998 (2016)
  324. Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. Zhong L, Haynes L, Struble EB, Tamin A, Virata-Theimer ML, Zhang P. Biochem Biophys Res Commun 390 1056-1060 (2009)
  325. AutoMatch: target-binding protein design and enzyme design by automatic pinpointing potential active sites in available protein scaffolds. Zhang C, Lai L. Proteins 80 1078-1094 (2012)
  326. Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation. Jette CA, Barnes CO, Kirk SM, Melillo B, Smith AB, Bjorkman PJ. Nat Commun 12 1950 (2021)
  327. Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant. Totrov M. PLoS One 9 e94002 (2014)
  328. Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. Sastry M, Xu L, Georgiev IS, Bewley CA, Nabel GJ, Kwong PD. J Biomol NMR 50 197-207 (2011)
  329. Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120. Chen H, Xu X, Lin HH, Chen SH, Forsman A, Aasa-Chapman M, Jones IM. J Gen Virol 89 2597-2604 (2008)
  330. Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120. Shrivastava IH, Wendel K, LaLonde JM. Biochemistry 51 7783-7793 (2012)
  331. Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies. Blanchetot C, De Jonge N, Desmyter A, Ongenae N, Hofman E, Klarenbeek A, Sadi A, Hultberg A, Kretz-Rommel A, Spinelli S, Loris R, Cambillau C, de Haard H. J Biol Chem 291 13846-13854 (2016)
  332. Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. Pan R, Chen Y, Vaine M, Hu G, Wang S, Lu S, Kong XP. Emerg Microbes Infect 4 e44 (2015)
  333. The challenge of developing universal vaccines. Rappuoli R. F1000 Med Rep 3 16 (2011)
  334. The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies. Peachman KK, Wieczorek L, Polonis VR, Alving CR, Rao M. Virology 408 213-223 (2010)
  335. Antibodies to HIV-1: aiming at the right target. Eggink D, Melchers M, Sanders RW. Trends Microbiol 15 291-294 (2007)
  336. Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin. Ramage W, Gaiotto T, Ball C, Risley P, Carnell GW, Temperton N, Cheung CY, Engelhardt OG, Hufton SE. Antibodies (Basel) 8 E14 (2019)
  337. Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody. Clark KR, Walsh ST. Protein Sci 18 2429-2441 (2009)
  338. Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding. Shrivastava I, LaLonde JM. Biochemistry 50 4173-4183 (2011)
  339. Hydroponic Treatment of Nicotiana benthamiana with Kifunensine Modifies the N-glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression. Roychowdhury S, Oh YJ, Kajiura H, Hamorsky KT, Fujiyama K, Matoba N. Front Plant Sci 9 62 (2018)
  340. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120. Tan H, Rader AJ. Proteins 74 881-894 (2009)
  341. News Mapping the future of HIV vaccines. Nabel GJ. Nat Rev Microbiol 5 482-484 (2007)
  342. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development. Yuan T, Li J, Zhang Y, Wang Y, Streaker E, Dimitrov DS, Zhang MY. Vaccine 29 6903-6910 (2011)
  343. Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. Kaplan G, Roitburd-Berman A, Lewis GK, Gershoni JM. J Virol 90 4481-4493 (2016)
  344. The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies. Dueñas-Decamp MJ, O'Connell OJ, Corti D, Zolla-Pazner S, Clapham PR. Retrovirology 9 9 (2012)
  345. Comment Vaccinology: A sweet cleft in HIV's armour. Sattentau QJ. Nature 480 324-325 (2011)
  346. A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. Wegmann F, Krashias G, Lühn K, Laamanen K, Vieira S, Jeffs SA, Shattock RJ, Sattentau QJ. PLoS One 6 e15861 (2011)
  347. Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity. Drummer HE, Hill MK, Maerz AL, Wood S, Ramsland PA, Mak J, Poumbourios P. PLoS Pathog 9 e1003218 (2013)
  348. Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based array. Gallerano D, Ndlovu P, Makupe I, Focke-Tejkl M, Fauland K, Wollmann E, Puchhammer-Stöckl E, Keller W, Sibanda E, Valenta R. PLoS One 10 e0117204 (2015)
  349. Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions. Wang Z, Lorin C, Koutsoukos M, Franco D, Bayat B, Zhang Y, Carfi A, Barnett SW, Porter F. Vaccines (Basel) 4 E17 (2016)
  350. Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond. Sanders RW, Hsu ST, van Anken E, Liscaljet IM, Dankers M, Bontjer I, Land A, Braakman I, Bonvin AM, Berkhout B. Mol Biol Cell 19 4707-4716 (2008)
  351. Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. Vassell R, He Y, Vennakalanti P, Dey AK, Zhuang M, Wang W, Sun Y, Biron-Sorek Z, Srivastava IK, LaBranche CC, Montefiori DC, Barnett SW, Weiss CD. PLoS One 10 e0128562 (2015)
  352. Nanostructure and force spectroscopy analysis of human peripheral blood CD4+ T cells using atomic force microscopy. Hu M, Wang J, Cai J, Wu Y, Wang X. Biochem Biophys Res Commun 374 90-94 (2008)
  353. Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Guo W, Cleveland B, Davenport TM, Lee KK, Hu SL. Protein Expr Purif 90 34-39 (2013)
  354. Structure of an HIV-2 gp120 in Complex with CD4. Davenport YW, West AP, Bjorkman PJ. J Virol 90 2112-2118 (2016)
  355. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. Zhang Y, Yuan T, Li J, Zhang Y, Xu J, Shao Y, Chen Z, Zhang MY. AIDS 27 2529-2539 (2013)
  356. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Da LT, Quan JM, Wu YD. Proteins 79 1810-1819 (2011)
  357. A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide. Martin G, Sun Y, Heyd B, Combes O, Ulmer JB, Descours A, Barnett SW, Srivastava IK, Martin L. Virology 381 241-250 (2008)
  358. Anti-idiotypic monobodies derived from a fibronectin scaffold. Sullivan MA, Brooks LR, Weidenborner P, Domm W, Mattiacio J, Xu Q, Tiberio M, Wentworth T, Kobie J, Bryk P, Zheng B, Murphy M, Sanz I, Dewhurst S. Biochemistry 52 1802-1813 (2013)
  359. Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Visciano ML, Tuen M, Chen PD, Hioe CE. Infect Agent Cancer 3 11 (2008)
  360. Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. Pahar B, Kenway-Lynch CS, Marx P, Srivastav SK, LaBranche C, Montefiori DC, Das A. Virol J 13 200 (2016)
  361. Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures. Nakamura KJ, Heath L, Sobrera ER, Wilkinson TA, Semrau K, Kankasa C, Tobin NH, Webb NE, Lee B, Thea DM, Kuhn L, Mullins JI, Aldrovandi GM. Retrovirology 14 6 (2017)
  362. Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. Rawi R, Kunji K, Haoudi A, Bensmail H. PLoS One 10 e0143245 (2015)
  363. Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. Bancroft T, DeBuysscher BL, Weidle C, Schwartz A, Wall A, Gray MD, Feng J, Steach HR, Fitzpatrick KS, Gewe MM, Skog PD, Doyle-Cooper C, Ota T, Strong RK, Nemazee D, Pancera M, Stamatatos L, McGuire AT, Taylor JJ. J Exp Med 216 2331-2347 (2019)
  364. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. Chuang GY, Lai YT, Boyington JC, Cheng C, Geng H, Narpala S, Rawi R, Schmidt SD, Tsybovsky Y, Verardi R, Xu K, Yang Y, Zhang B, Chambers M, Changela A, Corrigan AR, Kong R, Olia AS, Ou L, Sarfo EK, Wang S, Wu W, Doria-Rose NA, McDermott AB, Mascola JR, Kwong PD. J Virol 94 e00074-20 (2020)
  365. Glycosylation assists binding of HIV protein gp120 to human CD4 receptor. Wilhelm D, Behnken HN, Meyer B. Chembiochem 13 524-527 (2012)
  366. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States. Johnson J, Zhai Y, Salimi H, Espy N, Eichelberger N, DeLeon O, O'Malley Y, Courter J, Smith AB, Madani N, Sodroski J, Haim H. J Virol 91 e00174-17 (2017)
  367. Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120. Sang P, Yang LQ, Ji XL, Fu YX, Liu SQ. PLoS One 9 e104714 (2014)
  368. Methods development for Analysis of Partially Deglycosylated Proteins and Application to an HIV Envelope Protein Vaccine Candidate. Go EP, Hewawasam GS, Ma BJ, Liao HX, Haynes BF, Desaire H. Int J Mass Spectrom 305 209-216 (2011)
  369. Peptide Paratope Mimics of the Broadly Neutralizing HIV-1 Antibody b12. Haußner C, Damm D, Nirschl S, Rohrhofer A, Schmidt B, Eichler J. Chembiochem 18 647-653 (2017)
  370. Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120. Chandramouli B, Chillemi G, Giombini E, Capobianchi MR, Rozera G, Desideri A. J Biomol Struct Dyn 31 403-413 (2013)
  371. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. Yuan T, Li J, Zhang MY. MAbs 3 402-407 (2011)
  372. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H. J Gen Virol 91 1354-1364 (2010)
  373. Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Ouyang Y, Yin Q, Li W, Li Z, Kong D, Wu Y, Hong K, Xing H, Shao Y, Jiang S, Ying T, Ma L. Sci Rep 7 6222 (2017)
  374. Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1. Solanki AK, Rathore YS, Badmalia MD, Dhoke RR, Nath SK, Nihalani D, Ashish. J Biol Chem 289 34780-34800 (2014)
  375. Congress Reflecting on a quarter century of HIV research. Armitage AE, McMichael AJ, Drakesmith H. Nat Immunol 9 823-826 (2008)
  376. Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. Heydarchi B, Center RJ, Gonelli C, Muller B, Mackenzie C, Khoury G, Lichtfuss M, Rawlin G, Purcell DF. PLoS One 11 e0157353 (2016)
  377. Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. Hodge EA, Naika GS, Kephart SM, Nguyen A, Zhu R, Benhaim MA, Guo W, Moore JP, Hu SL, Sanders RW, Lee KK. iScience 25 104449 (2022)
  378. Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5. Hu G, Liu J, Roux KH, Taylor KA. J Virol 91 e00134-17 (2017)
  379. The High Content of Fructose in Human Semen Competitively Inhibits Broad and Potent Antivirals That Target High-Mannose Glycans. Johnson J, Flores MG, Rosa J, Han C, Salvi AM, DeMali KA, Jagnow JR, Sparks A, Haim H. J Virol 94 e01749-19 (2020)
  380. Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography. Dutta M, Liu J, Roux KH, Taylor KA. J Virol 88 12265-12275 (2014)
  381. CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. Dreja H, Pade C, Chen L, McKnight Á. J Gen Virol 96 1899-1905 (2015)
  382. HIV p24 as scaffold for presenting conformational HIV Env antigens. Tagliamonte M, Marasco D, Ruggiero A, De Stradis A, Tornesello ML, Totrov M, Buonaguro FM, Buonaguro L. PLoS One 7 e43318 (2012)
  383. Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies. Yang Z, Li J, Liu Q, Yuan T, Zhang Y, Chen LQ, Lou Q, Sun Z, Ying H, Xu J, Dimitrov DS, Zhang MY. PLoS One 10 e0126428 (2015)
  384. Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. Yang Z, Dam KA, Bridges MD, Hoffmann MAG, DeLaitsch AT, Gristick HB, Escolano A, Gautam R, Martin MA, Nussenzweig MC, Hubbell WL, Bjorkman PJ. Nat Commun 13 732 (2022)
  385. Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120. Meier J, Kassler K, Sticht H, Eichler J. Beilstein J Org Chem 8 1858-1866 (2012)
  386. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. Amos JD, Himes JE, Armand L, Gurley TC, Martinez DR, Colvin L, Beck K, Overman RG, Liao HX, Moody MA, Permar SR. J Virol 89 9485-9498 (2015)
  387. Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. Kumar R, Visciano ML, Li H, Hioe C. J AIDS Clin Res S8 5512 (2012)
  388. The emerging shape of a global HIV research agenda: how partnerships between Northern and Southern researchers are addressing questions relevant to both. Mgone C. Curr Opin HIV AIDS 3 521-525 (2008)
  389. Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env. Heydarchi B, Center RJ, Bebbington J, Cuthbertson J, Gonelli C, Khoury G, Mackenzie C, Lichtfuss M, Rawlin G, Muller B, Purcell D. MAbs 9 550-566 (2017)
  390. An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. Isik G, Chung NP, van Montfort T, Menis S, Matthews K, Schief WR, Moore JP, Sanders RW. PLoS One 8 e67309 (2013)
  391. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18. Gift SK, Zentner IJ, Schön A, McFadden K, Umashankara M, Rajagopal S, Contarino M, Duffy C, Courter JR, Zhang MY, Gershoni JM, Cocklin S, Dimitrov DS, Smith AB, Freire E, Chaiken IM. Biochemistry 50 2756-2768 (2011)
  392. Cross-crystal averaging with search models to improve molecular replacement phases. Li W, Li F. Structure 19 155-161 (2011)
  393. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. Tartaglia LJ, Gupte S, Pastores KC, Trott S, Abbink P, Mercado NB, Li Z, Liu PT, Borducchi EN, Chandrashekar A, Bondzie EA, Hamza V, Kordana N, Mahrokhian S, Lavine CL, Seaman MS, Li H, Shaw GM, Barouch DH. J Virol 94 e01860-19 (2020)
  394. Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. Stieh DJ, Phillips JL, Rogers PM, King DF, Cianci GC, Jeffs SA, Gnanakaran S, Shattock RJ. Retrovirology 10 33 (2013)
  395. Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41. Khasawneh AI, Laumaea A, Harrison DN, Bellamy-McIntyre AK, Drummer HE, Poumbourios P. Retrovirology 10 44 (2013)
  396. Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. Chen W, Feng Y, Wang Y, Zhu Z, Dimitrov DS. Biochem Biophys Res Commun 425 931-937 (2012)
  397. Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro. Devito C, Ellegård R, Falkeborn T, Svensson L, Ohlin M, Larsson M, Broliden K, Hinkula J. Sci Rep 8 10180 (2018)
  398. Modeling the three-dimensional structures of an unbound single-chain variable fragment (scFv) and its hypothetical complex with a Corynespora cassiicola toxin, cassiicolin. Malik A, Firoz A, Jha V, Sunderasan E, Ahmad S, Ahmad S. J Mol Model 16 1883-1893 (2010)
  399. Rational design of vaccines for AIDS and influenza. Nabel GJ. Trans Am Clin Climatol Assoc 123 9-15; discussion 15-6 (2012)
  400. Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01. Chikaev AN, Bakulina AY, Burdick RC, Karpenko LI, Pathak VK, Ilyichev AA. PLoS One 10 e0120847 (2015)
  401. Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization. Ringe R, Das L, Choudhary I, Sharma D, Paranjape R, Chauhan VS, Bhattacharya J. PLoS One 7 e46713 (2012)
  402. A Bistable Switch in Virus Dynamics Can Explain the Differences in Disease Outcome Following SIV Infections in Rhesus Macaques. Ciupe SM, Miller CJ, Forde JE. Front Microbiol 9 1216 (2018)
  403. A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain α1 helix in an engineered HIV-1 gp120. Emileh A, Abrams CF. Proteins 79 537-546 (2011)
  404. CD4 binding determinant mimicry for HIV vaccine design. Nishiyama Y, Planque S, Hanson CV, Massey RJ, Paul S. Front Immunol 3 383 (2012)
  405. Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy. Emileh A, Duffy C, Holmes AP, Rosemary Bastian A, Aneja R, Tuzer F, Rajagopal S, Li H, Abrams CF, Chaiken IM. Biochemistry 53 3403-3414 (2014)
  406. Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods. Li L, Wei W, Jia WJ, Zhu Y, Zhang Y, Chen JH, Tian J, Liu H, He YX, Yao X. J Comput Aided Mol Des 31 1053-1062 (2017)
  407. Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies. Lopez T, Chuan C, Ramirez A, Chen KE, Lorenson MY, Benitez C, Mustafa Z, Pham H, Sanchez R, Walker AM, Ge X. Biotechnol Bioeng 115 2673-2682 (2018)
  408. Identification of a high affinity nucleocapsid protein binding element from the bovine leukemia virus genome. Yildiz FZ, Babalola K, Summers MF. Virus Res 171 278-286 (2013)
  409. Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection. de Bree GJ, Wheatley AK, Lynch RM, Prabhakaran M, Grijsen ML, Prins JM, Schmidt SD, Koup RA, Mascola JR, McDermott AB. PLoS One 12 e0173577 (2017)
  410. Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes. Koh WW, Forsman A, Hué S, van der Velden GJ, Yirrell DL, McKnight A, Weiss RA, Aasa-Chapman MM. J Gen Virol 91 2374-2380 (2010)
  411. Pharmacological descriptors related to the binding of Gp120 to CD4 corresponding to 60 representative HIV-1 strains. Calborean O, Mernea M, Avram S, Mihailescu DF. J Enzyme Inhib Med Chem 28 1015-1025 (2013)
  412. Structural dynamics of V3 loop in a trimeric ambiance, a molecular dynamics study on gp120-CD4 trimeric mimic. Chandramouli B, Chillemi G, Desideri A. J Struct Biol 186 132-140 (2014)
  413. Congress Structures and diseases. Wendt KU, Weiss MS, Cramer P, Heinz DW. Nat Struct Mol Biol 15 117-120 (2008)
  414. Vaccine design reaches the atomic level. Kwong PD, Shapiro L. Sci Transl Med 3 91ps29 (2011)
  415. Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. Roitburd-Berman A, Dela G, Kaplan G, Lewis GK, Gershoni JM. Retrovirology 10 147 (2013)
  416. Letter Can HIV p24 be a suitable scaffold for presenting Env antigens? Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Clin Vaccine Immunol 18 2003-2004 (2011)
  417. Cross-Reactive Potential of HIV-1 Subtype C-Infected Indian Individuals Against Multiple HIV-1 Potential T Cell Epitope Gag Variants. Negi N, Vajpayee M, Singh R, Sharma A, Murugavel KG, Ranga U, Thakar M, Sreenivas V, Das BK. Viral Immunol 29 572-582 (2016)
  418. Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles. Purwar M, Pokorski JK, Singh P, Bhattacharyya S, Arendt H, DeStefano J, La Branche CC, Montefiori DC, Finn MG, Varadarajan R. Vaccine 36 6345-6353 (2018)
  419. Display of the HIV envelope protein at the yeast cell surface for immunogen development. Mathew E, Zhu H, Connelly SM, Sullivan MA, Brewer MG, Piepenbrink MS, Kobie JJ, Dewhurst S, Dumont ME. PLoS One 13 e0205756 (2018)
  420. Exploring converse molecular mechanisms of anti-HIV-1 antibodies using a synthetic CXCR4 mimic. Haussner C, Möbius K, Eichler J. Bioorg Med Chem Lett 22 6099-6102 (2012)
  421. Functional mimetic of the G-protein coupled receptor CXCR4 on a soluble antibody scaffold. Koksal AC, Pennini ME, Marelli M, Xiao X, Dall'Acqua WF. MAbs 11 725-734 (2019)
  422. HIV-1 rational vaccine design: molecular details of b12-gp120 complex structure. Phogat SK, Kaminsky SM, Koff WC. Expert Rev Vaccines 6 319-321 (2007)
  423. Immunology of infants through adolescents: responses to emulate for HIV vaccines. Jaspan HB, Hanekom WA. Curr Opin HIV AIDS 2 391-398 (2007)
  424. Mathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections. Ciupe SM. J Math Biol 71 513-532 (2015)
  425. Motifier: An IgOme Profiler Based on Peptide Motifs Using Machine Learning. Ashkenazy H, Avram O, Ryvkin A, Roitburd-Berman A, Weiss-Ottolenghi Y, Hada-Neeman S, Gershoni JM, Pupko T. J Mol Biol 433 167071 (2021)
  426. Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1. Xiang SH. Curr HIV Res 11 464-472 (2013)
  427. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope. Takizawa M, Miyauchi K, Urano E, Kusagawa S, Kitamura K, Naganawa S, Murakami T, Honda M, Yamamoto N, Komano J. AIDS 25 2209-2216 (2011)
  428. Role of human CD4 D1D2 domain in HIV-1 infection. Li L, Shi X, Lu Q, Zhang S, Wang X, Jiang X, Liu Y, Wang G, Zhu W, Lei R, Wu H. Immunol Invest 42 106-121 (2013)
  429. Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. Zhou T, Chen L, Gorman J, Wang S, Kwon YD, Lin BC, Louder MK, Rawi R, Stancofski ED, Yang Y, Zhang B, Quigley AF, McCoy LE, Rutten L, Verrips T, Weiss RA, VRC Production Program, Doria-Rose NA, Shapiro L, Kwong PD. Structure 30 862-875.e4 (2022)
  430. Structure and design of broadly-neutralizing antibodies against HIV. Ryu SE, Hendrickson WA. Mol Cells 34 231-237 (2012)
  431. Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry. Ugwu-Korie N, Quaye O, Wright E, Languon S, Agyapong O, Broni E, Gupta Y, Kempaiah P, Kwofie SK. Molecules 28 474 (2023)
  432. T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell. Liu S, Sun J, Li Z, Qin L, Liu G, Li K, Wu H, Dong T, Zhang Y. Front Immunol 10 437 (2019)
  433. The molecular mechanism of two coreceptor binding site antibodies X5 and 17b neutralizing HIV-1: Insights from molecular dynamics simulation. Zhang Y, Guo J, Huang L, Tian J, Yao X, Liu H. Chem Biol Drug Des 92 1357-1365 (2018)
  434. Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design. Hu D, Bowder D, Wei W, Thompson J, Wilson MA, Xiang SH. Vaccine 35 3067-3075 (2017)
  435. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. Fetzer I, Davis-Gardner ME, Gardner MR, Alfant B, Weber JA, Prasad NR, Zhou AS, Farzan M. J Virol 93 e01653-18 (2019)
  436. News Complex binding sites made to order. Scott JK, Pantophlet R, Craig L. Nat Biotechnol 30 154-155 (2012)
  437. Construction of a recombinant full-length membrane associated IgG library. Sun Z, Lu S, Yang Z, Li J, Zhang MY. Virus Res 238 156-163 (2017)
  438. Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner. Patil S, Choudhary I, Chaudhary NK, Ringe R, Bansal M, Shukla BN, Boliar S, Chakrabarti BK, Bhattacharya J. Virology 462-463 266-272 (2014)
  439. Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses. Marichannegowda MH, Mengual M, Kumar A, Giorgi EE, Tu JJ, Martinez DR, Romero-Severson EO, Li X, Feng L, Permar SR, Gao F. Cell Rep Med 2 100315 (2021)
  440. Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network. Shrivastava I, LaLonde JM. Proteins 78 2935-2949 (2010)
  441. HIV-1 envelope accessible surface and polarity: clade, blood, and brain. Sowmya G, Shamini G, Anita S, Sakharkar M, Mathura V, Rodriguez H, Levine AJ, Singer E, Commins D, Somboonwit C, Sinnott JT, Sidhu HS, Rajaseger G, Pushparaj PN, Kangueane P, Shapshak P. Bioinformation 6 48-56 (2011)
  442. Insights into the interaction of CD4 with anti-CD4 antibodies. Bui VC, Nguyen TH. Immunobiology 222 148-154 (2017)
  443. Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01. Cardozo-Ojeda EF, Perelson AS. Front Immunol 12 710012 (2021)
  444. Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda. Palaia JM, McConnell M, Achenbach JE, Gustafson CE, Stoermer KA, Nolan M, Guay LA, Leitner TK, Matovu F, Taylor AW, Fowler MG, Janoff EN. J Infect 68 264-272 (2014)
  445. Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads. Caulfield MJ, Dudkin VY, Ottinger EA, Getty KL, Zuck PD, Kaufhold RM, Hepler RW, McGaughey GB, Citron M, Hrin RC, Wang YJ, Miller MD, Joyce JG. J Biol Chem 285 40604-40611 (2010)
  446. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cottrell CA, Manne K, Kong R, Wang S, Zhou T, Chuang GY, Edwards RJ, Henderson R, Janowska K, Kopp M, Lin BC, Louder MK, Olia AS, Rawi R, Shen CH, Taft JD, Torres JL, Wu NR, Zhang B, Doria-Rose NA, Cohen MS, Haynes BF, Shapiro L, Ward AB, Acharya P, Mascola JR, Kwong PD. Cell Rep 37 109922 (2021)
  447. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12. Sterjovski J, Churchill MJ, Ellett A, Wesselingh SL, Ramsland PA, Gorry PR. Virology 432 394-404 (2012)
  448. Use of mutual information arrays to predict coevolving sites in the full length HIV gp120 protein for subtypes B and C. Wei B, Han N, Liu HZ, Rayner A, Rayner S. Virol Sin 26 95-104 (2011)
  449. Interview An audience with... Rino Rappuoli. Rappuoli R. Nat Rev Drug Discov 6 694 (2007)
  450. CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. Sarkar S, Spencer DA, Barnette P, Pandey S, Sutton WF, Basu M, Burch RE, Cleveland JD, Rosenberg AF, Rangel-Moreno J, Keefer MC, Hessell AJ, Haigwood NL, Kobie JJ. Front Immunol 12 757811 (2021)
  451. IgG1-b12-HIV-gp120 Interface in Solution: A Computational Study. Martí D, Alemán C, Ainsley J, Ahumada O, Torras J. J Chem Inf Model 62 359-371 (2022)
  452. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge. Davis D, Koornstra W, Fagrouch Z, Verschoor EJ, Heeney JL, Bogers WM. PLoS One 8 e72702 (2013)
  453. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Lei R, Kim W, Lv H, Mou Z, Scherm MJ, Schmitz AJ, Turner JS, Tan TJC, Wang Y, Ouyang WO, Liang W, Rivera-Cardona J, Teo C, Graham CS, Brooke CB, Presti RM, Mok CKP, Krammer F, Dai X, Ellebedy AH, Wu NC. Immunity 56 2621-2634.e6 (2023)
  454. Machine Learning Prediction and Phyloanatomic Modeling of Viral Neuroadaptive Signatures in the Macaque Model of HIV-Mediated Neuropathology. Ramirez-Mata AS, Ostrov D, Salemi M, Marini S, Magalis BR. Microbiol Spectr e0308622 (2023)
  455. Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity. Kassler K, Sticht H. J Biomol Struct Dyn 32 52-64 (2014)
  456. Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120. Gift SK, McFadden K, Zentner IJ, Rajagopal S, Zhang MY, Dimitrov DS, Chaiken IM. Biochemistry 50 2769-2779 (2011)
  457. Polyreactivity of antibodies from different B-cell subpopulations is determined by distinct sequence patterns of variable region. Lecerf M, Lacombe RV, Dimitrov JD. Front Immunol 14 1266668 (2023)
  458. Study on molecular mechanisms of CD4 dependency and independency of HIV-1 gp120. Liu MT, Shen JX, Li XW, Yang L, Li Y, Sang P, Yang LQ. RSC Adv 13 6274-6286 (2023)
  459. News Winning or losing: where are we in the fight against HIV and AIDS? Honey K. J Clin Invest 117 2348 (2007)


Quick links